Adam Lee

Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020

Kristina L. Bajema, Ryan E. Wiegand, Kendra M. Cuffe et al. · JAMA Internal Medicine · 2020 · 322 citations · Full text

Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022

Kristie E.N. Clarke, Jefferson M. Jones, Yangyang Deng et al. · MMWR Morbidity and Mortality Weekly Report · 2022 · 320 citations · Full text

Virus Epidemiology, Immunology, Population Health Sciences +17

Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States—October 25, 2020–February 26, 2022

Ryan E. Wiegand, Yangyang Deng, Xiaoyi Deng et al. · The Lancet Regional Health - Americas · 2022 · 58 citations · Full text

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

David P. Carbone, Tudor–Eliade Ciuleanu, Michael Schenker et al. · Journal for ImmunoTherapy of Cancer · 2024 · 56 citations · Full text

Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.

Adam Lee, Hany Ezzeldin, Jeanne Fourie et al. · PubMed · 2004 · 54 citations

Molecular Pharmacology, Dpyd Gene, Biochemistry +14